BMS' Opdivo evens the score in melanoma with 2 new FDA green lights
Thanks to an FDA decision over the weekend, Bristol-Myers Squibb's immunotherapy Opdivo has caught back up to Merck's Keytruda in melanoma. And it won a new combination approval from the FDA to boot. Last fall, the FDA handed Keytruda a lead in advanced melanoma, approving the Merck drug for previously untreated patients regardless of the genetic characteristics of their tumors.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063